NEW YORK, March 20, 2017 /PRNewswire/ --
Stock-Callers.com today has initiated coverage on MannKind Corp. (NASDAQ:MNKD), Opko Health Inc. (NASDAQ: OPK), Celgene Corp. (NASDAQ: CELG), and Array BioPharma Inc. (NASDAQ: ARRY). These companies are engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic
Valencia, California headquartered MannKind Corp.'s stock finished last Friday's session 7.25% higher at $2.22. A total volume of 4.57 million shares was traded, which was above their three months average volume of 4.38 million shares. The Company's shares have skyrocketed 316.51% in the past month, 270.00% over the previous three months, and 248.67% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 153.73% and 175.50%, respectively. Additionally, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the US, have a Relative Strength Index (RSI) of 83.90.
On March 16th, 2017, MannKind announced that total revenue for Q4 2016 was $12.4 million, including $10.2 million from insulin sales to Sanofi, and net income for Q4 2016 was $54.0 million including $72.0 million from the extinguishment of debt owed to Sanofi. The Company finished 2016 with $22.9 million of cash and cash equivalents. Visit us today and download your complete report on MNKD for free at:
On Friday, shares in Miami, Florida headquartered Opko Health Inc. ended the session 2.87% lower at $8.12. The stock recorded a trading volume of 10.59 million shares, which was higher than its three months average volume of 4.87 million shares. The Company's shares are trading 4.48% below their 50-day moving. Moreover, shares of Opko Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, and Mexico, have an RSI of 47.48.
On March 14th, 2017, OPKO Health announced that its subsidiary GeneDx has been selected to present research data in 14 poster presentations and 4 platform presentations at the American College of Medical Genetics and Genomics Annual Meeting taking place from March 21st-24th, 2017 in Phoenix, Arizona. The complimentary research report on OPK can be accessed at:
Summit, New Jersey headquartered Celgene Corp.'s shares declined 0.67%, closing the session at $125.77. A total volume of 6.14 million shares was traded, which was higher than their three months average volume of 4.07 million shares. The stock has gained 4.40% in the last one month, 8.58% over the previous three months, and 8.66% on an YTD basis. The Company's shares are trading 6.00% and 13.15% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have an RSI of 62.39.
On March 05th, 2017, Celgene announced results from its phase-4 UNVEIL trial evaluating OTEZLA® (apremilast). The UNVEIL study evaluated the clinical efficacy and safety of oral OTEZLA 30 mg twice daily compared with placebo at week 16 in 221 patients with moderate plaque psoriasis who were naďve to systemic and biologic therapy. At week 16, patients who received OTEZLA had a significantly greater improvement in mean percentage change from baseline in PGA×BSA compared with those who received placebo.
On March 09th, 2017, research firm UBS initiated a 'Buy' rating on the Company's stock, with a target price of $140 per share. Register for free on Stock-Callers.com and download the PDF research report on CELG at:
Last Friday at the close, shares in Boulder, Colorado headquartered Array BioPharma Inc. recorded a trading volume of 9.27 million shares, which was above their three months average volume of 4.03 million shares. The stock ended the session 1.68% lower at $10.56. The Company's shares have advanced 20.82% over the previous three months and 20.14% since the start of this year. The stock is trading above its 200-day moving average by 57.16%. Furthermore, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 40.03.
On March 19th, 2017, Array BioPharma announced that it has withdrawn from the US Food and Drug Administration's (FDA) Division of Oncology Products 2 its new drug application (NDA) for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, a rare, mutationally-driven subset of skin cancer. This action was based on thorough discussions and communications with the FDA, including exploration of various paths to approval, and followed the late cycle review meeting held with the FDA on March 17th, 2017. Get free access to your research report on ARRY at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!